NCT02955940 2025-12-17
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Incyte Corporation
Phase 2 Active not recruiting
Clinical Trials
60 trialsNCT04753879 2025-12-04
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT01972919 2025-10-27
MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT02598349 2025-09-09
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Proton Collaborative Group
Phase 2 Recruiting
NCT03073785 2025-05-25
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
University of Nebraska
Phase 2 Active not recruiting
NCT03523312 2025-05-02
MAIBE
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT00881621 2025-03-03
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
Georgetown University
Phase 2 Terminated
NCT03563144 2025-02-21
QUILT-3.088: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT06110598 2024-08-15
CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT03351296 2024-05-08
BETTER2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Active not recruiting
NCT04371224 2024-04-19
NaliCap
Seoul National University Hospital
Phase 2 Recruiting
NCT01525082 2024-02-06
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Stanford University
Phase 2 Completed
NCT06202014 2024-01-19
Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05415917 2023-08-22
Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy
Rutgers, The State University of New Jersey
Phase 2 Unknown
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT01845337 2023-05-12
TOFFEE
University of Edinburgh
Phase 2 Completed
NCT05566743 2022-10-04
A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas
Menoufia University
Phase 2 Unknown
NCT01360593 2022-03-08
Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
University of Pittsburgh
Phase 2 Completed
NCT04089150 2021-10-22
MASTERPLAN
Australasian Gastro-Intestinal Trials Group
Phase 2 Unknown
NCT01591733 2021-05-28
FOLFIRINOX + RT for Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Unknown
NCT01459614 2021-05-19
Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01494155 2021-02-02
Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Unknown
NCT00114179 2020-10-30
Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT02981342 2019-11-20
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
Eli Lilly and Company
Phase 2 Completed
NCT02301143 2019-03-20
LAPACT
Celgene
Phase 2 Completed
NCT01760252 2019-03-15
Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol
Beth Israel Medical Center
Phase 2 Terminated
NCT01032057 2018-10-26
SCALOP
Cardiff University
Phase 2 Completed
NCT00276744 2018-10-24
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT01534637 2018-08-15
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT00408564 2018-07-23
Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Medical University of South Carolina
Phase 2 Completed
NCT01921751 2018-07-13
High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Radiation Therapy Oncology Group
Phase 2 Terminated
NCT02767752 2018-07-10
CHIPAC
Herlev Hospital
Phase 2 Terminated
NCT01423604 2018-02-12
RECAP
Incyte Corporation
Phase 2 Completed
NCT00290693 2017-12-02
Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer
University of Miami
Phase 2 Completed
NCT00833859 2017-10-09
Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01150630 2017-09-01
PACT-15
IRCCS San Raffaele
Phase 2 Completed
NCT00609336 2017-07-13
Perioperative Therapy for Resectable Pancreatic Cancer
University of Washington
Phase 2 Completed
NCT00585078 2017-04-10
Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00601627 2017-04-05
Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02565641 2016-11-02
A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00869050 2016-07-25
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Phase 2 Completed
NCT00882310 2016-07-25
A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer
Columbia University
Phase 2 Completed
NCT00996333 2016-07-25
Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)
Columbia University
Phase 2 Completed
NCT00869258 2016-06-22
Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar
Columbia University
Phase 2 Completed
NCT00100815 2015-12-24
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT01754623 2015-08-13
GTX-RT in Borderline Resectable Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01167738 2015-04-24
PACT-17
IRCCS San Raffaele
Phase 2 Terminated
NCT01130701 2015-03-17
PMABIIS
University of Massachusetts, Worcester
Phase 2 Withdrawn
NCT00962312 2014-12-31
Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer
Cancer Trials Ireland
Phase 2 Completed
NCT00372944 2014-08-13
AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy
AstraZeneca
Phase 2 Completed